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Abstract
Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome
P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking.
Subjects were tested for 10 CYP2D6 allelic variants and copy number status, and
activity scores assigned to each genotype. Seventy-six individuals (median 0.3
[range 0–26] years old) were included. Propafenone AEs occurred in 29 (38%); 14
(18%) required drug discontinuation due to AE. The most common AEs were QRS
(n = 10) and QTc (n = 6) prolongation. Those with AEs were older at the time of
propafenone initiation (1.58 [0.13–9.92] vs. 0.20 [0.08–2.01] years old; p = 0.042).
CYP2D6 activity scores were not associated with presence of an AE (odds ratio
[OR] 0.48 [0.22–1.03]; p = 0.055) but with the total number of AE (β1 = −0.31
[−0.60, −0.03]; p = 0.029), systemic AEs (OR 0.33 [0.13–0.88]; p = 0.022), and drug
discontinuation for systemic AEs (OR 0.28 [0.09–0.83]; p = 0.017). Awareness of
CYP2D6 activity score and patient age may aid in determining an individual's risk
for an AE with propafenone administration.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Use of propafenone, an antiarrhythmic medication, may result in cardiac and/
or systemic adverse events (AEs). Previous studies in adults demonstrated metabolizer status is associated with AEs; however, this has not been studied in the
pediatric population.
WHAT QUESTION DID THIS STUDY ADDRESS?
The primary objective of this study was to assess the relationship between
CYP2D6 activity score and propafenone AEs in pediatric and young adult patients. The secondary objective was to test for associations of clinical characteristics to propafenone AEs.
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for the analyses described were
obtained from Vanderbilt University
Medical Center’s BioVU which is
supported by numerous sources:
institutional funding, private agencies,
and federal grants. These include the
NIH funded Shared Instrumentation
Grant S10RR025141; and Clinical and
Translational Science Award grants
UL1TR002243, UL1TR000445, and
UL1RR024975. Genomic data are
also supported by investigator-led
projects that include U01HG004798,
R01NS032830, RC2GM092618,
P50GM115305, U01HG006378,
U19HL065962, R01HD074711; and
additional funding sources listed at
https://victr.vumc.org/biovu-funding/.
This project utilized REDCap, funded
by UL1 TR000445 from NCATS/NIH.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study demonstrates an association of CYP2D6 activity score with (1)
systemic AEs, (2) drug discontinuation due to systemic AEs, and (3) total number
of AEs. In addition, older patients were more likely to have an AE while on
propafenone.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
These data provide the first evidence of a relationship between CYP2D6 activity
score and propafenone AEs in children and young adults. Thus, awareness of
CYP2D6 activity score and patient age may aid in determining an individual‘s risk
for an AE with propafenone administration.

I N T RO DU CT ION
Supraventricular tachycardia occurs in up to 1 in 250
healthy children and 1 in 6 children with congenital
heart disease.1,2 At our institution, propafenone is an
option as a first-line enteral antiarrhythmic medication
in pediatric patients with or without congenital heart
disease diagnosed with supraventricular tachycardia.
Propafenone is a Vaughn-Williams class 1C antiarrhythmic drug that primarily blocks the cardiac sodium channel, and has a weak beta blocking effect.3 The primary
metabolism of propafenone is to 5-hydroxypropafenone
and N-
desalkyl-
propafenone by the cytochrome P450
2D6 (CYP2D6) enzyme; CYP3A4 and CYP1A2 enzymes
have also been reported to contribute to drug metabolism.3,4 5-
Hydroxypropafenone is an active metabolite
with equipotent sodium channel blocking capabilities to
propafenone.
The CYP2D6 gene is highly polymorphic with common
genetic variants including single nucleotide variants and
copy number variants (including gene deletions and duplications, CYP2D6-2D7 and CYP2D7-2D6 hybrid genes,
and complex combinations of the aforementioned) leading to a wide spectrum of enzyme activity.5,6 Based on
genetic testing, predicted CYP2D6 activity scores can be
calculated and individuals categorized as poor, intermediate, normal, or ultrarapid metabolizers.7 As expected,
slower CYP2D6 metabolism leads to higher drug levels of
propafenone in vitro and in vivo, but the clinical impact
of these differences in drug concentration are not well
established.8–10
Adverse events (AEs) commonly associated with
propafenone are electrocardiogram (ECG) changes
(atrioventricular nodal block, QRS or QTc prolongation,

and bradycardia) and systemic symptoms (dysgeusia, increased secretions, gagging, dizziness, hypotension, fatigue, and headache). Previous reports have described
propafenone AE frequency to range between 4% and
27%.11–15 CYP2D6 activity scores have been associated
with propafenone pharmacokinetics, but there are limited
data on the association between CYP2D6 activity scores
and AEs, particularly in the pediatric population.4,9,10,16,17
The primary aim of our study was to test the hypothesis
that CYP2D6 activity scores are associated with AEs in the
pediatric and young adult population. Secondary aims included reporting the incidence and clinical risk factors of
propafenone AEs for these patients.

METHODS
Study design
This was a single-
center, retrospective, observational
study using BioVU, an institutional biobank linking DNA
to de-identified electronic health records (EHR) data at
Vanderbilt University Medical Center (VUMC).18–21 The
VUMC IRB determined that this study was non-human
subjects research based on US Health & Human Services
(HHS) regulation 45 CFR 46.102(f). Individuals for inclusion were initially identified through an automated
search, followed by manual review of the record. Search
criteria included those less than 30 years of age with
propafenone mentioned in the EHR. Additional inclusion criteria confirmed through manual review were: (1)
at least one documented administration of propafenone
and (2) at least one clinical note from a VUMC provider
managing propafenone. Exclusion criteria were: (1) no
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evidence of propafenone administration; (2) propafenone
used as pill-in-pocket as-needed abortive therapy; or (3)
insufficient documentation of a patient's clinical course
while on propafenone in order to determine presence or
absence of AEs.

Clinical and outcome data
Demographic, clinical, and outcome data were collected
manually for each patient by a single reviewer (S.D.S.).
Demographic, clinical, and outcome data were stored in
REDCap, an electronic data management tool housed by
VUMC.22,23 Demographic data included age, race, and
ethnicity as recorded in the EHR. Clinical data included
presence of congenital heart disease, single ventricle anatomy, need for surgical intervention, arrhythmia diagnosis,
and duration and dose of propafenone use including the
starting and maximum dose indexed to body surface area.
Use of concomitant antiarrhythmics, CYP2D6 inducers,
and inhibitors were recorded.24 Collection of outcome
data was performed blinded to CYP2D6 genotype and
activity score. Reason for propafenone discontinuation
was categorized as refractory arrhythmia, intolerance of
propafenone AE, completion of therapy following ablation or spontaneous resolution of arrhythmia, and patient
non-adherence.
The case status for AEs during propafenone use was
determined by discussion of each potential case with
electrophysiologists (P.J.K., A.E.R., F.A.F.) at our institution. Potential AEs were identified via chart review and
included if they occurred within the first 3 years of drug
therapy. ECG changes defined as AEs included atrioventricular nodal block, prolongation of QRS or QTc intervals, and bradycardia. Designation of prolonged QRS or
QTc interval was determined by clinical documentation
of the attending physician as there are no clear definitions in the literature for prolonged QRS or QTc while on
propafenone. Baseline PR, QRS, and QTc intervals while
on propafenone were recorded from the most recent ECG
obtained prior to propafenone administration. Intervals
while on propafenone were measured by recording the
average interval from ECGs during therapy. In patients
who underwent heart surgery and required propafenone
in the postoperative period, ECG changes that occurred
intraoperatively or within 24 h postoperatively were not
attributed to propafenone AE.
Gastrointestinal (GI) AEs were defined as dysgeusia
and GI intolerance, which encompassed increased secretions, gagging, decreased appetite, or poor feeding. In neonates and infants, it can be difficult to discern if increased
secretions and gagging are due to drug AE or normal newborn behavior; therefore, these were included as AEs only
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if it was a clear change from baseline, led to poor weight
gain, or was documented as the reason for medication
discontinuation, with resolution after drug discontinuation. Neurologic side effects were defined as dizziness,
headaches, flushing, fatigue, and irritability. Systemic AEs
encompassed hypotension, neurologic AEs, and GI AEs.
If an AE was present, the number of days from propafenone initiation to first AE and dose at the time of AE were
recorded, as well as the total number of different AEs
observed.

Genetic data
CYP2D6 genotyping was performed for each individual
if a DNA sample was available. Testing was carried out
by Vanderbilt Technologies for Advanced Genomics
(VANTAGE) laboratory using reagents and protocols
as recommended by the manufacturer. Genotyping and
copy number assays were performed using commercially available TaqMan assays (Thermo Fisher Scientific,
Waltham, MA). Eleven CYP2D6 single nucleotide variants
(rs28371706, rs16947, rs59421388, rs1080985, rs35742686,
rs3892097, rs1065852, rs28371725, rs5030655, rs5030867,
and rs5030656) were tested which allowed assignment
of 10 variant alleles: CYP2D6*2, *3, *4, *6, *7, *9, *10, *17,
*29, and *41. Copy number was detected by using assays
targeting intron 6 and exon 9. A normal function allele
(CYP2D6*1) was assigned if no variants were identified.
CYP2D6 activity score and metabolizer status were assigned as recommended by the Clinical Pharmacogenetics
Implementation Consortium (CPIC) and used in their
guidelines (Tables S1 and S2).5,25,26 CYP2D6 allele calls
and activity score assignments were determined and
agreed upon by two of the authors (A.G., S.L.V.).

Statistical analysis
Statistical analyses were performed using Stata version
16 (Stata Corp., College Station, TX). Univariate analysis using logistic regression was performed to test for an
association between presence of an AE and CYP2D6 activity score. An analysis was performed for those greater
than and less than 1 year of age as this represented an age
threshold at which therapy for supraventricular tachycardia can often be discontinued. With respect to demographic and clinical features, categorical variables were
compared with Pearson's Chi square and continuous variables with Wilcoxon rank sum. Log rank statistical test
was performed to assess difference in freedom from AE
analysis. Logistic regression was performed to calculate
odds ratio of activity score for AE analysis and AE subset
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analyses. Linear regression was performed to test for association between activity score and total number of AEs
observed. All statistical tests were two-sided and p values
<0.05 were considered statistically significant.

RES ULT S
Cohort demographics and clinical data
A total of 76 individuals met the criteria and were included in the analyses (Table 1). The median age at time
of propafenone initiation was 0.3 (range 0–26) years. The
median initial dose of propafenone was 235 (interquartile
range [IQR] 230–350) mg/m2/day. Of the 76 subjects, 45
(59%) had congenital heart disease and 42 (55%) underwent surgery for congenital heart disease. Amongst those
with congenital heart disease, 21 (47%) had single ventricle physiology. The most common arrhythmias were atrial
tachycardia and atrioventricular reciprocating tachycardia. Beta blockers (33%) were the most common concomitant antiarrhythmic used (Table S3).

AE outcomes
AEs were seen in 29 (38%) individuals in this cohort. The
most common AEs (Figure 1) were prolonged QRS (median increase of 18 [16–27] ms; n = 10) and QTc intervals
(median increase 20 [17–40] ms; n = 6). Those without QRS
prolongation had median increase in QRS of 10 (−1, 16)
ms. Those without QTc prolongation had average increase
in QTc of 5 (−8, 40) ms. Baseline median intervals for QRS
and QTc amongst all patients were 78 (68–96) ms and 442
(417–466) ms, respectively. First degree (median increase
31 [20–42] ms; n = 4) and second-degree (n = 4) atrioventricular nodal block were also seen with propafenone use.
Baseline median PR interval for the cohort was 114 (98–130)
ms. No pro-arrhythmic events were observed. The most
common systemic AEs included dizziness (n = 3), dysgeusia (n = 3), fatigue (n = 3), and GI intolerance (n = 3). Side
effect profile was the reason for drug discontinuation in 14
patients. Of these, common AEs leading to drug discontinuation included prolonged QRS (n = 4), dysgeusia (n = 3),
and fatigue (n = 3). Propafenone was discontinued in 11
patients due to inefficacy (refractory arrhythmia).

Characteristic

No adverse event Adverse event
(n = 47)
(n = 29)
Total (n = 76)

Age (years)†

0.2 (0.1–2.0)

1.6 (0.1–9.9)

0.3 (0.1–5.9)

Female

19 (40%)

14 (48%)

33 (43%)

36 (77%)

21 (72%)

57 (75%)

African American

6 (13%)

4 (14%)

10 (13%)

Hispanic

5 (11%)

2 (7%)

7 (9%)

Asian

0 (0%)

1 (3%)

1 (1%)

Other

0 (0%)

1 (3%)

1 (1%)

EHR-recorded race
Caucasian

Deceased

6 (13%)

1 (3%)

7 (9%)

Propafenone duration (days)

191 (49–492)

144 (54–659)

186 (51–603)

Initial dose of propafenone
(mg/m2/day)

240 (200–300)

228 (200–250)

235 (230–350)

Maximum dose of propafenone
(mg/m2/day)

283 (240–354)

250 (225–300)

250 (230–350)

Congenital heart disease

27 (57%)

18 (62%)

45 (59%)

Congenital heart surgery‡

26 (96%)

16 (89%)

42 (93%)

Single ventricle anatomy‡

11 (41%)

10 (56%)

21 (47%)

Concomitant use of CYP2D6
inhibitor

16 (34%)

7 (24%)

23 (30%)

Concomitant use of CYP2D6
inducer

1 (2%)

1 (3%)

2 (3%)

Note: Data are presented as median (IQR) for continuous measures and n (%) for categorical measures.
Categorical variables were compared with Pearson's Chi square and continuous variables with Wilcoxon
rank sum. EHR, electronic health record.
†

Statistically significant between adverse event and non-adverse event groups (p < 0.05).

‡

Percentages based on those with congenital heart disease.

T A B L E 1 Demographic and clinical
characteristics
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ECG Adverse Events
Systemic Adverse Events

10

Count (n)

8

6

4

2

0

Adverse Event Observed
< 1yo

≥ 1yo

F I G U R E 1 Propafenone adverse events. Histogram displaying adverse events (AEs) in those above (blue) and below (red) 1 year of age.
AEs listed to the left of the dashed line represent electrocardiogram-associated AEs, while systemic AEs are shown to the right of the dashed
line. ECG, electrocardiogram; GI, gastrointestinal.

Those with AEs were older at the time of propafenone initiation (1.58 [0.13–9.92] vs. 0.20 [0.08–2.01]
years; p = 0.042). There was no difference in age between those with and without ECG-
related AEs;
however, those with a systemic AE (9.08 [2.54–18.25]
years) were older than those without a systemic AE
(0.21 [0.08–2.19] years). When dichotomized by age,
those above 1 year of age were more likely to have
AEs (17/29, 59% vs. 12/47, 25%; p = 0.004) and require
propafenone discontinuation due to AE profile (10/29,
35% vs. 4/47, 9%; p = 0.005). Time to event analysis
(Figure 2) demonstrated a difference in freedom from
AE between those above and below 1 year of age
(p = 0.004). Of the 29 patients with an AE, 69% (20/29)
had an AE within 90 days of propafenone initiation.
Excluding age, there were no differences for any other
demographic or clinical variables between the AE and
non-AE groups (Tables 1, S3).

Associations of AEs with CYP2D6 activity
score or phenotype
DNA samples were available for 69 of the 76 individuals (Table 2). The most common metabolizer status in
this cohort was normal metabolizer (n = 43) followed
by intermediate metabolizer (n = 20); the distribution of
genotype data and activity scores is shown in Table S2
and Figure S1. Univariate analysis demonstrated no
association between activity score and presence of
any AE (odds ratio [OR] 0.48, 95% confidence interval
[0.22–1.03]; p = 0.055). Results were not significantly
different in multivariable analysis correcting for age,
maximum propafenone dose indexed for body surface
area, and use of CYP2D6 inhibitors or inducers. There
was no use of strong CYP3A4 or CYP1A2 inhibitors
in this cohort.24 When analyzing total number of AEs
(Figure 3), linear regression demonstrated an inverse
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F I G U R E 2 Effect of age on freedom
from adverse event (AE). Kaplan–Meier
curve demonstrating time to AE in those
above (blue) and below (red) 1 year of
age at time of propafenone initiation.
Log-rank statistical test was performed to
assess for difference (p value = 0.004). Of
the 29 patients with an AE, 69% (20/29)
had an AE within 90 days of propafenone
initiation.

0.00

Proportion Free From AE
0.25
0.50
0.75

1.00

1792

0

200

400

600
Days to AE

< 1 year old (n=47)

TABLE 2

800

1000

≥ 1 year old (n=29)

Metabolizer status compared to clinical outcomes

Clinical outcome

Poor
(n = 4)

Intermediate
(n = 20)

Normal
(n = 43)

Ultrarapid
(n = 2)

Unknown
(n = 7)

Any adverse event (%)

2 (50%)

10 (50%)

14 (33%)

0 (0%)

3 (43%)

ECG adverse event (%)

1 (25%)

6 (30%)

11 (26%)

0 (0%)

2 (29%)

Systemic adverse event (%)

1 (25%)

6 (30%)

5 (12%)

0 (0%)

1 (14%)

Discontinuation due to adverse event (%)

1 (25%)

5 (25%)

8 (19%)

0 (0%)

0 (0%)

Note: Outcome data relative to metabolizer classification. Genetic data were unavailable for seven patients. Additional supporting information may be found in
the online version of the article on the publisher's website.
Abbreviation: ECG, electrocardiogram.

relationship between activity score and total number of
AEs (β1 = −0.31 [−0.60, −0.03]; p = 0.029).
Activity score had an OR of 0.47 [0.20–1.14] (p = 0.094)
for propafenone discontinuation due to an AE (n = 14).
Subset AE analysis was performed classifying AEs into
ECG and systemic AEs. Higher CYP2D6 activity score was
not associated with ECG AEs (OR 0.91 [0.41–2.06]) but
was associated with fewer systemic AEs (OR 0.33 [0.13–
0.88]; p = 0.022) and less drug discontinuation due to systemic AE (n = 9, OR 0.28 [0.09–0.83]; p = 0.017). Activity
score was not associated with discontinuation due to drug
inefficacy (n = 11, OR 0.71 [0.27–1.85]). Linear regression
revealed CYP2D6 activity score was not associated with
average PR, QRS, or QTc intervals.

DI S C US S I O N
To the best of our knowledge, this is the first study assessing the association between CYP2D6 genetic variability
(i.e., activity scores) and propafenone AEs in the pediatric

population. In this single-
center, retrospective pediatric study, we found that lower CYP2D6 activity scores
trended towards increased risk of AEs and drug discontinuation due to AE; this was, however, only statistically
significant for systemic AEs. We also found that individuals ≥1 year of age were more likely to have AEs. These
data suggest that CYP2D6 activity score and age may be
important considerations when prescribing propafenone
and monitoring for AEs.
Studies focused on specific CYP2D6 alleles and
propafenone drug concentrations have demonstrated
that CYP2D6 poor metabolizers had higher drug concentrations.9,27–30 An adult study utilizing debrisoquine as phenotype probe and urinary metabolic ratios,
which serves as a surrogate measure of CYP2D6 activity, reported an increased risk of neurologic AEs with
propafenone in poor metabolizers compared to ultrarapid metabolizers.16 Similarly, in our study a significant
association between activity score and systemic AEs
was observed. Furthermore, we detected an association
between activity score and drug discontinuation due to
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30

25

Count (n)

20

≥ 2 AEs

15

1 AE

10

None

5
0

0

0.5

0.75

1

1.25

1.5

2

2.5

3

Acvity Score
F I G U R E 3 Total adverse events (AEs) by activity score. Stacked histogram demonstrating the frequency of total AEs for each activity
score. Legend corresponds to the total number of AEs for a given patient. Amongst those with a CYP2D6 genotype and activity score, 42/69
had no AE (blue), 16/69 had one AE (yellow), 10/69 had two AEs (red), and one had three AEs (red). Linear regression demonstrated an
inverse relationship between activity score and total number of AEs (β1 = −0.31 [−0.60, −0.03]; p = 0.029).

systemic AEs. For those with multiple AEs, lower activity scores were associated with an increasing number
of AEs as demonstrated by linear regression analysis.
These data provide the first insights and evidence supporting such relationships.
Our study comports with previous adult studies that
demonstrated no significant difference in QRS or QTc prolongation based on metabolizer status.16,28 It is challenging to understand why activity score is associated with
systemic AEs, but not ECG-associated AEs. One possible
explanation is the presence of propafenone metabolites.
5-Hydroxypropafenone is known to have electrophysiologic
properties; however, its effect on systemic AEs is not well
understood. Future studies quantifying metabolite concentrations in subjects with known metabolizer status and presence of cardiac and systemic AEs could test these theories.
Differential beta blocker effect has been observed in poor
versus normal metabolizers with low dose, but not high dose
propafenone,31 raising the possibility that at therapeutic
doses of propafenone, CYP2D6 metabolizer status may not
be associated with ECG outcomes. In addition, propafenone
is often titrated for its cardiac effects, which are monitored
via ECG. It is plausible that early and significant changes in
QRS or QTc duration may prompt dose adjustment prior to
the detection and recording of an AE in the EHR.
An association between age and propafenone AEs has
not been previously described in the literature. At our institution, newborns and infants with supraventricular tachycardia are maintained on antiarrhythmic therapy until 1
year, at which time a transesophageal electrophysiology

study is performed. If no arrhythmia is inducible, medication is discontinued; therefore, we had a special interest
in this population, prompting the dichotomization time
point of 1 year of age for our analysis. The increased incidence of AEs in those ≥1 year of age could be secondary
to systemic AEs being subjective complaints, which cannot be elicited in those <1 year of age. Alternatively, there
may be differences in the pharmacokinetics or pharmacodynamics of the drug in infants. Metabolic pathways may
vary in younger and older infants, predisposing older children to systemic AEs. Previous studies have shown an increase in CYP2D6 activity in adults compared to neonates
that are postulated to occur rapidly after birth; therefore,
it is unclear if there are significant differences in CYP2D6
activity amongst children of different ages.32,33 There also
appears to be a decline in CYP2D6 activity beyond the
second decade of life.34 This association between age and
incidence of AEs is likely multifactorial in etiology. While
our study demonstrated a statistically significant result,
this should not preclude those ≥1 year of age from receiving propafenone when clinically indicated.
Guidelines from the Dutch Pharmacogenetics Working
Group recommend an empiric decrease by 70% of standard starting propafenone dose for poor metabolizers.4,35
In our cohort, two of four poor metabolizers had an AE.
Additionally, individuals classified as intermediate metabolizers had identical frequencies for AEs and discontinuation due to AE compared to those classified as poor
metabolizers. Lower rates of AE and drug discontinuation
due to AE were detected in normal metabolizers. However,
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adverse events did occur in this subgroup, indicating these
individuals are not invulnerable to AE or requiring drug
discontinuation due to AE. Lower activity scores were associated with increasing number of AEs and presence of
systemic AEs. This relationship should be further investigated and validated in a larger and more heterogeneous
cohort with increased sample size of poor metabolizers
and ultrarapid metabolizers. In the clinical setting, we
propose providers utilize drug efficacy and presence of
AEs to drive dosing changes, while being aware of patient
age and activity score as these may predispose to development of an AE. Also, the presence of an AE did not always
translate to immediate drug discontinuation as many of
the AEs were not life threatening. Awareness of patient
age and activity score can be beneficial to recognize those
who may be at risk for an AE, but do not necessarily require a preemptive change to starting dose. Larger cohort
studies are warranted to provide further insights into the
predictive ability of CYP2D6 genetic variation on AEs.

Limitations
The findings of this single-center, retrospective study may
not be generalizable to other sites or patient populations.
We also acknowledge that CYP2D6 genotype analysis only
included the more commonly observed variants and thus
rare alleles and some gene copy number variants may have
eluded detection. There was limited heterogeneity in metabolizer status, with few individuals categorized as poor
or ultrarapid metabolizers; therefore, it is difficult to draw
definitive conclusions for these individuals from these
data. The use of CYP2D6 inducers and inhibitors was not
associated with propafenone AE; however, propafenone
has several metabolic pathways. It is possible that other
drug–drug interactions, through these alternative pathways, could play a role in propafenone adverse events.
Cardiac AEs are predominantly captured via electrocardiogram or ambulatory heart rate monitor. There is
subjectivity in classifying QRS or QTc prolongation as
an AE as, to some degree, this is an expected effect of
propafenone. There is no universally accepted threshold
for classification of interval prolongation on propafenone.
We attempted to mitigate the subjectivity of this classification by attributing the designation of an AE based on the
documentation by the attending electrophysiologist rather
than by personnel involved in data collection.
Our study demonstrates that age at propafenone initiation and CYP2D6 genetic variation or activity score affect the frequency of propafenone AEs. Future directions
should include larger cohorts in order to capture a more
heterogenous population with respect to CYP2D6 activity
score, age, and ethnic diversity. Increased sample size of

poor and ultrarapid metabolizers is warranted to further
our understanding of the association between CYP2D6
genetic variation and metabolic capacity and drug discontinuation due to AE and inefficacy, respectively.
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